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We previously demonstrated that the oral antipsoria-
tic dimethylfumarate is an inhibitor of cytokine-
induced adhesion molecule expression in endothelial
HUVEC cells. We now report the inhibitory effect of
dimethylfumarate on tumor-necrosis-factor-a- or
interleukin-1a-induced intercellular adhesion mole-
cule 1 expression in normal human dermal ®bro-
blasts. Western blots of normal human dermal
®broblast cytoplasmic extracts showed that dimethyl-
fumarate has minor effects on the IkBa, b and e pro-
teins: their cytokine-induced degradation and
resynthesis is only slowed down, an effect most pro-
minently observed for IkBb. No inhibitory effect of
dimethylfumarate was observed on cytokine-induced
RelA/p65 or c-Rel accumulation in nuclear extracts
of cytokine-treated normal human dermal ®broblast
cells. In contrast, cytokine-induced nuclear factor
kB1/p50 nuclear accumulation was speci®cally inhib-
ited by dimethylfumarate. This inhibitory effect on
nuclear factor kB1 nuclear localization in normal
human dermal ®broblasts proved suf®cient to inhibit
nuclear factor kB1-RelA binding to nuclear factor
kB consensus oligonucleotides in DNA binding
assays. Likewise, cytokine-induced activation of a
pNFkB::luciferase reporter construct in transiently
transfected normal human dermal ®broblasts was
inhibited by dimethylfumarate. The observations
support a mechanistic model for the oral antipsoria-
tic dimethylfumarate in which lowering of nuclear
factor kB1 leads to changes in the nuclear factor
kB1-RelA nuclear balance and inhibition of cyto-
kine-induced adhesion molecule expression in nor-
mal human dermal ®broblasts. Key words: ICAM-1/
psoriasis/p50/p65. J Invest Dermatol 116:124±130, 2001
T
he attraction of leukocytes to peripheral tissues like
skin requires an in¯ammatory response of immune and
peripheral cells to external stimuli (Katz, 1993).
Epidermal keratinocytes, dermal ®broblasts, and en-
dothelial cells are activated both by the in¯ammatory
stimulus and by each other, to elaborate speci®c cytokines and
chemotactic factors that induce cell adhesion molecules (CAMs) on
their membranes (Barker et al, 1991a; Springer, 1994). These
CAMs react with speci®c integrins on the membrane of different
leukocytes (Nickoloff et al, 1990).
It was shown recently that dimethylfumarate (DMF), an active
ingredient of the oral antipsoriaticum Fumaderm, has an anti-
proliferative effect on keratinocytes (Thio et al, 1994), lymphocytes
(Nieboer et al, 1990), and ®broblasts (Van der Schroeff et al, 1989).
DMF also inhibits T cell cytokine secretion (Ockenfels et al, 1998),
expression on keratinocytes of intercellular adhesion molecule 1
(ICAM-1) (SeboÈk et al, 1994a), and cytokine-induced CAM
expression on endothelial cells (Vandermeeren et al, 1997). Normal
human dermal ®broblasts (NHDF) are also involved in the
initiation of an in¯ammatory response in the skin.
Proin¯ammatory cytokines produced by keratinocytes can upre-
gulate ICAM-1 on dermal ®broblasts (Boxman et al, 1996), whose
expression can also be inhibited by DMF, as shown in this study.
The mode of action of DMF is not completely understood, but
the inhibitory spectrum of DMF on cytokine-inducible genes
includes interleukin-6 (IL-6), E-selectin, vascular adhesion mole-
cule 1, and ICAM-1 (Vandermeeren et al, 1997; Ockenfels et al,
1998), all sharing a nuclear factor-kB (NF-kB) responsive element
in the cytokine-inducible enhancer of their gene promoters (May
and Gosh, 1998). This might indicate that DMF's molecular
mechanism of action interferes with the signaling cascades that
activate NF-kB (Prochaska et al, 1994).
NF-kB, a ubiquitous transcription factor, is a pivotal regulator of
immune responses, in¯ammation, cell proliferation, and apoptosis
(Baeuerle and Henkel, 1994; Gilmore et al, 1996). NF-kB
complexes are stored in the cytoplasm of unstimulated cells as
inactive complexes through interactions with a group of inhibitory
proteins called inhibitors of kB (IkB), such as IkBa, IkBb, IkBe.
Alternatively, IkB-like domains occur in NF-kB precursor proteins
p105 of NFkB1 (p50) and p100 of NFkB2 (p52) (Brown et al,
1995; Traenckner et al, 1995). Cytokines, such as IL-1a and tumor
necrosis factor a (TNF-a), rapidly induce NF-kB DNA binding
(Barnes and Karin, 1997), which comprises homodimers and
Manuscript received February 1, 2000; revised September 14, 2000;
accepted for publication October 19, 2000.
Reprint requests to: Dr. Vandermeeren Marc, Turnhoutseweg 30,
B-2340 Beerse, Belgium. Email: mvanderm@janbe.jnj.com
Abbreviations: DMF, dimethylfumarate; EMSA, electrophoretic mobi-
lity shift assay; IkB, inhibitor kB; NF-kB, nuclear factor kB; NHDF,
normal human dermal ®broblast; TPCK, n-tosyl-phenylalanine-chloro-
methylketon.
1 Equally contributing authors.
0022-202X/01/$15.00 ´ Copyright # 2001 by The Society for Investigative Dermatology, Inc.
124
heterodimers of Rel proteins such as RelA (p65), RelB, c-Rel,
NF-kB1 (p105/p50), and NF-kB2 (p100/p52) (Siebenlist et al,
1994).
This study shows that, in addition to inhibition of cytokine-
induced ICAM-1 expression, DMF also delays the reappearance of
the different IkB subunits in the cytoplasm of NHDF cells, possibly
by modifying the nuclear targeting machinery of NF-kB. The
molecular analysis of DMF's inhibitory effects have led to the
observation that inhibition of the translocation of NFkB1 (p50),
but not of RelA (p65), may underlie DMF's anti-in¯ammatory
effects.
MATERIALS AND METHODS
Cell culture NHDF, derived from neonatal skin, were obtained from
Clonetics (San Diego, CA) and cultured in either ®broblast growth
medium (Clonetics) or Optimem with Glutamax-1 (Gibco BRL, Life
Technologies, Paisley, U.K.) supplemented with 5% fetal bovine serum
(HyClone Laboratories, Logan, UT), 2 mM L-glutamine (Gibco BRL),
4 mg per ml gentamycin (Gibco BRL), and 1 mM sodium pyruvate (Gibco
BRL). They were used within the ®rst seven passages.
Reagents DMF and n-tosyl-phenylalanine-chloromethylketon (TPCK)
were purchased from Sigma (St. Louis, MO). Recombinant human TNF-a
and recombinant human IL-1a were obtained from Genzyme (Cambridge,
MA). Anti-ICAM-1 monoclonal antibody was purchased from Bender
Medsystems (Vienna, Austria). Normal goat serum was obtained from
DakoPatts (Glostrup, Denmark), and a secondary horseradish-peroxidase-
labeled goat antimouse antibody from Amersham (Buckinghamshire,
U.K.). Antibodies anti-p50 and anti-p65 to NF-kB subunits were
purchased from Biomol Research Labs (Plymouth Meeting, PA).
Polyclonal antibodies against IkB were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA): anti-IkBa, anti-IkBb, and anti-IkBe.
Anti-c-Rel antibody was also purchased from Santa Cruz Biotechnology.
Enzyme-linked immunosorbent assay (ELISA) NHDF were seeded
at 5000 cells per well in 96-well tissue culture plates (Nunc, Roskilde,
Denmark). Con¯uent cells received fresh medium plus pharmacologic
compounds at the indicated concentrations 1 h prior to stimulation. TNF-
a was added at 10 ng per ml and IL-1a at 3 U per ml. ICAM-1 expression
levels were determined after 24 h. Cell monolayers were washed ®ve times
with phosphate-buffered saline (PBS), ®xed for 15 min in 2%
paraformaldehyde, and blocked with 2% normal goat serum. After
blocking, a primary mouse antihuman anti-ICAM-1 monoclonal
antibody (50 ng per ml) was incubated for 3 h at room temperature or
overnight at 4°C. The monolayers were washed ®ve times, blocked, and
incubated for 1 h with a horseradish-peroxidase-conjugated goat antimouse
antibody (Amersham) diluted in 1% bovine serum albumin/PBS. The
amount of cell adhesion molecules was detected by a colorimetric method,
using phosphate-citrate buffer with urea hydrogen peroxide tablets (Sigma)
and ortho-phenylenediamine dihydrochloride (Sigma) as substrates. Adding
2 N sulfuric acid stopped the reaction and the absorbance was measured on
an ELISA plate reader at 490-650 nm. In a typical cell ELISA experiment,
quadruplicate plates are accompanied by a mitochondrial tetrazolium
(MTT) plate (method see below) to assess the effects of the treatment on
cell viability. Cell ELISA values are expressed as OD490±650nm/OD540±
650nm of the accompanying well in the MTT test.
Cell viability Cell viability was assessed with an MTT assay. Brie¯y,
NHDF cells were treated under the same conditions as described for the
cell ELISA experiments. After the incubation, 25 ml per well of an MTT
solution [5 mg per ml MTT (Sigma) in Ca2+/Mg2+-free PBS] was added
and incubated for 2 h. The medium was aspirated and replaced with 100 ml
per well isopropanol. The plates were shaken for 15 min and the OD was
measured at 540-650 nm.
Protein isolation NHDF cells were grown to 80%±90% con¯uence in
individual 75 cm2 ¯asks for preparation of extracts for each experimental
point. Following 1 h pretreatment with 100 mM DMF or 0.1%
dimethylsulfoxide and appropriate stimulus, ®broblasts were washed three
times in cold PBS, and protein was then extracted from the cells; cells were
resuspended in buffer A [10 mM HEPES KOH (pH 7.9) at 4°C, 1.5 mM
MgCl2, 10 mM KCl, 300 mM sucrose, 0.5% Nonidet P-40 with protease
inhibitor mixture (0.5 M dithiothreitol and 1 mM Pefabloc)]. Cells were
incubated for 5 min on ice and centrifuged for 10 s at 14,000 rpm at 4°C.
The resulting supernatant was the cytoplasmic fraction and cells were
washed once in buffer A. Pellets were resuspended in buffer C [20 mM
HEPES KOH (pH 7.9), 20% glycerol, 100 mM NaCl, 0.2 mM
ethylenediamine tetraacetic acid, 100 mM KCl with protease inhibitor
mixture] and frozen and thawed in liquid nitrogen. Next, pellets were
brie¯y sonicated and centrifuged at 14,000 rpm, resulting in the nuclear
fraction extracts. The supernatant was collected and the protein
concentration was quanti®ed using the Bio-Rad (Richmond, CA)
protein assay. The protein extracts were then stored at ±70°C until used
for electrophoretic mobility shift assay (EMSA) and western blot analysis.
Protein immunoblotting A total of 25±30 mg of protein extracts was
denatured at 95°C in 2 3 Laemmli buffer for 5 min, loaded onto 12% Tris
glycine sodium dodecyl sulfate (SDS) gel (BioRad), and electrophoresed at
30 mA constant. Protein was semidry blotted onto 0.2 mm polyvinylidene
di¯uoride membrane (Roche Diagnostic Corporation, Indianapolis, IN) in
transfer buffer for 1 h at 1 mA per cm2. The membranes were blocked with
5% (wt/vol) nonfat dry milk (BioRad) in PBS for 1 h, and incubated with
primary antibody overnight at 4°C. The membranes were then washed in
PBS-0.1% Tween-20 for 5 min with ®ve changes of buffer, and incubated
for 1 h with a horseradish-peroxidase-conjugated goat antirabbit antibody
(New England Biolabs, Beverly, MA) in 1:2000 dilution for 1 h at room
temperature. After washing, the bands of interest were visualized by
chemiluminescence (Pierce, Rockford, IL) and the light signal was
captured by a Lumi-Imager apparatus (Roche Diagnostic Corporation).
Polyclonal antibodies to IkBb, IkBe, p65, and p50 showed some
nonspeci®c bands. Bands of interest are indicated by arrows and veri®ed
by means of their exact molecular weight.
EMSA kB consensus oligo, 5¢-AGCTAGAGGGGACTTTCCGAG-
AGG, and the complementary strand were custom synthesized by
Eurogentec (Eurogentec, Liege, Belgium). The kB oligonucleotides were
annealed by mixing the single stranded oligonucleotides in a molar ratio of
1:1, incubating them for 10 min at 95°C, and cooling down slowly to 4°C.
NF-kB DNA binding was analyzed by incubating 8 mg nuclear proteins for
30 min at room temperature with the NF-kB speci®c 32P-labeled
oligonucleotide probe. Binding buffer consisted of 20 mM HEPES,
pH 7.5, 60 mM KCl, 4% Ficoll 400, 2 mM dithiothreitol, 100 mg per ml
poly-[d(I-C)], and 1 mg per ml bovine serum albumin. Samples were
analyzed by electrophoresis on a 5% native polyacrylamide gel that was run
for 1.5 h at 100 V in a 0.5 3 TBE buffer, pH 8.0. DNA-nucleoprotein
complex speci®city was determined by coincubation of nuclear extracts
with unlabeled homologous competitor DNA. For competition
experiments, 100-fold molar excess of unlabeled oligonucleotide was
included in the binding reaction. The following antibodies were used in
supershift experiments: antibodies anti-p50 (sc-114X) and anti-p65 (sc-
109X) to NF-kB subunits were purchased from Santa Cruz Biotechnology.
Brie¯y, antibodies were added to the nuclear extracts (1 mg polyclonal
antiserum per 8 mg nuclear protein) and incubated for 1 h before the
binding reaction.
Transfections NHDF cells were seeded at a density of 1 3 106 cells per
75 cm2 ¯ask. Twenty-four hours later, cells were transfected by
Lipofectamine (Gibco BRL) with constant 10 mg per 75 cm2 ¯ask of the
plasmid p(kB)3LUC, which has been described previously (Plaisance et al,
1997) and contains in front of the luciferase gene a minimal promoter for
the concanavaline A gene (a TATA binding site) preceded by three copies
of the NF-kB binding site of the major histocompatibility complex II gene.
Four hours after transfection, cells were trypsinized and seeded at 2 3 105
cells per 12 wells. At 42 h post transfection, cells were exposed to 100 mM
DMF or 0.1% dimethylsulfoxide (DMSO) vehicle for 1 h and further
stimulated with 10 ng per ml TNF-a for 4 h. This transfection was
performed ``in bulk''; therefore it was not necessary to correct results for
transfection ef®ciency. Transcriptional activity was corrected for total
protein content and the protein concentration was quanti®ed using Bio-
Rad protein assay.
RESULTS
DMF inhibits cytokine-induced ICAM-1 expression in
NHDF The effect of DMF on 10 ng per ml TNF-a- or 3 U
per ml IL-1a-induced ICAM-1 expression was studied using an in
situ ELISA (Fig 1). Treatment of the NHDF monolayers
diminished the expression of ICAM-1, both IL-1a and TNFa
induced, with an IC50 value of 30 mM, comparable with the IC50
of DMF on endothelial cells (Fig 1). Inhibition was complete at a
dose of 300 mM DMF. A cell viability assay was performed in
parallel with each in situ ELISA. DMF treatment was shown not to
affect cell viability of NHDF in parallel MTT assays (Fig 1)
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following 24 h of incubation, in contrast to 30 mM TPCK, a
proteasome inhibitor, which proved to be toxic to NHDF cells in
similar conditions.
DMF delays re-synthesis of IkBs To further understand DMF's
inhibitory effect on cytokine-induced ICAM-1 expression,
cytoplasmic extracts were subjected to western blotting to assay
the degradation kinetics of the different IkBs in NHDF cells. It was
shown (Fig 2) that after 100 mM DMF or 0.1% DMSO
pretreatment for 1 h and subsequent 10 ng per ml TNF-a or
25 U per ml IL-1a stimulation, IkBa and IkBe disappeared from
the cytoplasm after 15 min. IkBa proteins were re-synthesized after
30 min and IkBb and IkBe reappeared only after approximately 4 h.
There appeared to be minor differences in the degradation kinetics
for IkBs. IkBa and IkBe are being degraded slightly faster (at
15 min), whereas IkBb levels are minimal at 30 min following
cytokine stimulation. Re-synthesis of the IkBs in NHDF was
shown to be fast for IkBa and somewhat slower for IkBb and IkBe,
as demonstrated in other cells such as human U937 monocytic cells
(Nasuhara et al, 1999). Pre-incubation of con¯uent NHDF cells for
1 h with DMF followed by cytokine stimulation and incubation for
different time periods showed that DMF had minor inhibitory
effects on the degradation of IkBa and IkBe; however, IkBb
degradation was clearly inhibited. The reappearance of all IkBs in
the cytoplasm was signi®cantly delayed by DMF pretreatment
(Fig 2).
DMF inhibits NF-kB1 (p50) but not RelA (p65) nuclear
accumulation In parallel, the nuclear extracts of cytokine-
treated NHDF cells were western blot analyzed for the nuclear
targeting kinetics of NF-kBs. Both cytokines, 10 ng per ml TNF-a
and 25 U per ml IL-1a, induced an accumulation of the NF-kB
subunits p50 and p65 in nuclear extracts after 15 min (Fig 3). c-Rel
was found to be nuclear in unstimulated ®broblasts, and shifts to the
nucleus were shown not to occur following treatment with either
TNF-a or IL-1a (Fig 3). A 1 h DMF pretreatment did not
in¯uence p65 (nor c-Rel) nuclear translocation in western blots;
however, the appearance of p50 in the nucleus was clearly affected
by DMF (Fig 3). After TNF-a stimulation, p50 translocation was
still inhibited up to 4 h, but after IL-1a stimulation, delayed p50
nuclear accumulation appeared in the nucleus after 4 h (Fig 3).
Functional inhibition by DMF of NF-kB signaling To
further demonstrate that the inhibitory effects of DMF on ICAM-1
expression (and on delayed kB re-synthesis) were mediated by an
NF-kB-dependent mechanism, we tested whether DMF was
capable of inhibiting NF-kB protein binding to its kB DNA
binding site, by radioactive gel-shift performed with kB consensus
oligonucleotides. NHDF cells, 80%±90% con¯uent, were untreated
or stimulated with 10 ng per ml TNF-a for 2 h. A TNF-a-
inducible protein-DNA complex is clearly shown in Fig 4(a). A
100-fold molar excess of unlabeled homologous competitor NF-kB
oligonucleotide strongly reduced the TNF-a-induced complex.
This retarded complex was further identi®ed by supershift assays. In
a consecutive experiment (Fig 4b), again a TNF-a-inducible
protein-DNA complex was clearly shown versus a medium
control. When cells were pretreated with 100 mM DMF, DNA
oligo binding versus vehicle (DMSO) control in TNF-a-stimulated
cells was clearly decreased. When nuclear extracts of TNF-a-
treated cells were preincubated with an anti-p50 antibody or an
anti-p65 antibody, the cytokine-inducible complex band was less
intense and a supershift was observed with anti-p50 and anti-p65
antibodies, indicating that both p50 and p65 are components of the
NF-kB binding complexes.
Finally, we tested if DMF had an effect on the NF-kB
transcriptional activity by transient transfection experiments of
NHDF cells using a pNFkB::luciferase reporter gene construct
containing three repeat NF-kB binding sites. A 100 mM DMF
pretreatment of 1 h was shown to inhibit the transcription initiation
capacity of NF-kB in NHDF cells stimulated for 4 h with 10 ng
per ml TNF-a (Fig 5) or with 25 U per ml IL-1a (data not shown).
Total protein concentration of the individual samples was identical
after compound treatment.
DISCUSSION
Several clinical studies have shown that oral administration of
derivatives of fumarate is an effective treatment for psoriasis patients
(Mrowietz et al, 1998). ``Fumaric acid therapy'' consists of the oral
administration of a mixture of esteri®ed fumaric acid derivatives, in
which DMF is thought to be the main active ingredient as it exerts
the most pronounced antiproliferative activity in vitro in the
``subtoxic dose range'' (Thio et al, 1994) on keratinocytes (SeboÈk
et al, 1994b), lymphocytes (Nieboer et al, 1990), and ®broblasts
(Van der Schroeff et al, 1989). Due to its methylesters, DMF is a
lipid-soluble compound, with good cell permeability. Following
esterase conversion to fumarate, DMF enters the citric acid cycle at
the level of succinate dehydrogenase. This in turn is thought to
cause inhibition of cell functions, such as a decrease in proliferation
Figure 1. DMF inhibits cytokine-induced
ICAM-1 expression in NHDF. In situ ELISA of
ICAM-1 expression 24 h postinduction by 10 ng
per ml TNF-a or 3 U per ml IL-1a, with or with-
out 60 min pretreatment with different com-
pounds. The ELISA was performed as described
in Materials and Methods. Values represent mean
6 SD with n = 3. Graphs also show the result of
parallel MTT assays, which are performed as de-
scribed in Materials and Methods. The open circle is
the DMSO control. Values represent means.
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and perhaps cytotoxicity (Van der Schroeff et al, 1989). In our
observations, as in those for endothelial cells (Vandermeeren et al,
1997), 100 mM DMF showed no cytotoxic effects on NHDF
monolayer cultures even after prolonged incubation times of 24 h
either in the presence or absence of cytokines. This critically
suggests that the observed inhibitory effects do not result from a
direct cytotoxic mechanism.
Although the aforementioned studies underscore DMF's anti-
proliferative effects on cells, there is a growing body of evidence for
an anti-in¯ammatory mechanism of DMF. Such a mechanism is
re¯ected by observations of immune cells: suppression of produc-
tion and release of in¯ammatory mediators in granulocytes (Barker
et al, 1991b), augmentation of T helper cell 2 cytokine responses
(de Jong et al, 1996), modulation of T cell cytokine secretion, and
inhibition of cytokines of the psoriatic cytokine network
(Ockenfels et al, 1998). On the other hand, DMF also inhibits
cytokine-induced activation of peripheral cells such as adhesion
molecule expression in HUVEC cells (Vandermeeren et al, 1997)
and in this report cytokine-induced ICAM-1 expression in NHDF
cells. A widely accepted model for the anti-in¯ammatory mode of
action of DMF is the intracellular induction of enzymes responsible
for the synthesis and the maintenance of the antioxidant
glutathione, as shown for the monocytoid U1 cell line and human
retinal pigment epithelial cells (Prochaska et al, 1994; Nelson et al,
1999). Cytokine stimulation of cells is known to increase reactive
oxygen levels in the cells and leads to modi®cation of the IkB-NF-
kB balance. DMF's antioxidant property might partially explain our
observations on the inhibition of the cytokine-induced ICAM-1
upregulation in NHDF. Previous studies have shown that DMF
can abrogate the NF-kB pathway. This was demonstrated by the
EMSA technique (NF-kB consensus oligonucleotide) in a phorbol-
myristate-acetate-stimulated monocytoid U1 cell line (Prochaska
et al, 1994), and in arsenite-activated porcine aortic endothelial cells
(Barchowsky et al, 1996). Besides phorbol-myristate-acetate- and
arsenite-induced NF-kB binding, this study now demonstrates that
DMF also inhibits NF-kB binding in reporter assays and gel
mobility assays following TNF-a and IL-1a stimulation (IL-1a
data not shown).
Based on these observations, DMF is one on an increasing list of
compounds that display inhibition of NF-kB activation.
Experiments to identify where exactly in the NF-kB pathway
DMF acts have led to the observation that DMF speci®cally
inhibited p50 nuclear translocation without affecting p65 nuclear
translocation. This observation of a p65-independent p50 inhibi-
tion supports the data of a recent study (Heissmeyer et al, 1999) that
suggested a bifurcation of the NF-kB-activating pathways down-
stream of the IkB kinase (IKK) complex to IkBa and p105
complexes. Our observations in NHDF pinpoint DMF's putative
target of action upstream of p50 nuclear accumulation, perhaps at
the level of p105 degradation, as has been shown for glucocorti-
Figure 2. DMF delays re-synthesis of IkBs.
DMF (r) and DMSO solvent control (n).
NHDF cells were treated with 0.1% DMSO or
100 mM DMF for 60 min and then stimulated with
TNF-a (10 ng per ml) or IL-1a (25 U per ml) for
0, 15, 30, 60, and 240 min. Cytosolic protein was
extracted and 30 mg of protein was subjected to
SDS-PAGE followed by immunoblotting with
IkBa, IkBb, and IkBe antibodies using the en-
hanced chemiluminescence technique as described
in Materials and Methods. Shown is a representative
result of three independent experiments.
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coids in vivo (Cornstein et al, 1999). Our data do not exclude a
mechanism of DMF on nuclear regulatory components of kB
signaling such as Bcl-3, an IkB-like nuclear protein that activates
cytoplasmic p50 homodimers or p50-p105 heterodimers and
translocates them to the nucleus (Watanabe et al, 1997). The close
correlation between the kinetics of p50 nuclear accumulation and
reappearance of the three IkBs following DMF treatment suggests
that p50 is an essential regulator in IkB re-synthesis and that
possibly p65 alone is not suf®cient to drive IkB transcription in
NHDF cells.
The speci®city of DMF's inhibitory effect on NFkB1/p50
speci®c nuclear accumulation has not been observed ± to the best of
our knowledge ± for other compounds that interfere with kB
signaling. Aspirin inhibits TNF-a-induced NF-kB mobilization in
human endothelial cells (Weber et al, 1995), and salicylates and
¯avonoids in general are thought to mediate this effect through
inhibition of IKK in TNF-a-induced endothelial cells (Bayon et al,
1999; Tsai et al, 1999; Yamamoto et al, 1999). Curcumin
(diferuloylmethane) has been proposed to inhibit NF-kB signaling
(Kumar et al, 1998), possibly through direct protein binding and
modi®cation of NFkB1/p50 in Jurkat T lymphoma cells, like
herbimycin A ± a tyrosine kinase inhibitor ± binds directly with p50
in T lymphocytes (Mahon and O'Neill, 1995; Brennan and
O'Neill, 1998), or by inhibiting a signal leading to and upstream of
NF-kB-inducing kinase (NIK) and IKK in human colonic
epithelial cells (Jobin et al, 1999). The antioxidant pyrrolidine
dithiocarbamate (PDTC) inhibited NF-kB in TNF-a-induced
human endothelial cells and human ®broblasts in an EMSA assay
(Ferran et al, 1995; Kawai et al, 1995). PDTC requires zinc for NF-
kB inhibition in bovine endothelial cells, however (Kim et al,
1999). N-(3-aminopropionyl)-L-histidinato zinc (polaprezinc)
downregulates NF-kB by an inhibition of IkBa phosphorylation
in gastric epithelial cells (Shimada et al, 1999). Proteasome
inhibitors in an intestinal epithelial cell line (Jobin et al, 1998),
protein tyrosine kinase inhibitors in human myeloid T cells
(Natarajan et al, 1998), and protein tyrosine phosphatase inhibitors
in human endothelial cells (Dhawan et al, 1997) have all been
shown to interact with NF-kB signaling by a partially understood
molecular mechanism. The mechanism of action of glucocorticoids
has been extensively investigated, but their mode of action in NF-
kB signaling is still controversial: both inhibition and stimulation of
NF-kB or IkBa have been observed (for a review see Dumont et al,
1998; McKay and Cidlowski, 1998). 1a,25-dihydroxyvitamin D3
targets only DNA binding of NF-kB in human ®broblasts but does
not inhibit nuclear accumulation of the subunits p50 and p65
(Harant et al, 1998), perhaps through a squelching (Freedman,
1999) or phosphorylation-dependent mechanism. 3-deazaadeno-
sine, an S-adenosylhomocystein hydrolase inhibitor, has a dual
Figure 3. DMF inhibits NFkB1 (p50) but not
RelA (p65) nuclear accumulation. DMF (n)
and DMSO solvent control (r). Vehicle (0.1%
DMSO) or 100 mM DMF treatments were per-
formed for 60 min and then stimulated with
TNF-a (10 ng per ml) or IL-1a (25 U per ml) for
0, 15, 30, 60, and 240 min. Nuclear protein was
extracted and 30 mg of protein was subjected to
SDS-PAGE followed by immunoblotting of p65,
p50, and c-Rel, using the enhanced chemilumi-
nescence technique as described in Materials and
Methods. Translocation of c-Rel and p65 was un-
changed after DMF treatment. Cells pretreated
with DMF, however, clearly inhibited or delayed
p50 translocation to the nucleus. Shown is a re-
presentative result of three independent experi-
ments.
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effect on NF-kB regulation by blocking of p65 (RelA) phosphor-
ylation without reduction of its nuclear translocation and by
inhibition of DNA binding activity in mouse macrophages (Jeong
et al, 1999). On the other hand, mesalamine, an anti-in¯ammatory
aminosalicylate, in epithelial cells (Egan et al, 1999) and genistein in
human U937 monocytic cells (Nasuhara et al, 1999) inhibit
cytokine-stimulated NF-kB-dependent transcription without pre-
venting IkB degradation or nuclear translocation and DNA binding
of the transcriptionally active NF-kB proteins p65, p50, and/or c-
Rel, suggesting the existence of additional mechanisms that
regulate NF-kB activation. Heyninck et al (1999) demonstrated
the existence of at least two different NF-kB pathways: a NIK-
mediated pathway leading to translocation of NF-kB to the
nucleus, and a NIK-independent pathway leading to transactivation
of NF-kB. Another study (Vlahopoulos et al, 1999) demonstrated
that, in U937 cells, TNF-a induces a delayed reactive-oxygen-
species-dependent signaling pathway that is required for NF-kB
transcriptional activation and is separable from that required for its
nuclear translocation. DMF could possibly attack, besides nuclear
translocation of p50, such a ``transactivation speci®c pathway of
NF-kB''. In this way p65 could still be translocated to the nucleus
and an NF-kB reporter construct could be abrogated, maybe by
inhibiting the NF-kB p65 coactivator CBP/p300 (Zhong et al,
1998).
In conclusion, the in vitro data for normal human dermal
®broblasts critically suggests that the p50 subunit of kB signaling
may be a target relevant to the anti-in¯ammatory activity of DMF
in psoriasis. Further studies will focus on the targets upstream and
downstream of p50 that are most probably tackled by DMF.
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Guy Daneels and Burkhard Haefner for critical reading of the manuscript.
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